Literature DB >> 25387096

Monitoring mycophenolate mofetil is necessary for the effective prophylaxis of acute GVHD after cord blood transplantation.

Y Arai1, T Kondo1, T Kitano1, M Hishizawa1, K Yamashita1, N Kadowaki1, T Yamamoto2, I Yano2, K Matsubara2, A Takaori-Kondo1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25387096     DOI： 10.1038/bmt.2014.258

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  11 in total

1.  Customized mycophenolate dosing based on measuring inosine-monophosphate dehydrogenase activity significantly improves patients' outcomes after renal transplantation.

Authors:  Matthias C Raggi; Stephanie B Siebert; Werner Steimer; Tibor Schuster; Manfred J Stangl; Dietmar K Abendroth
Journal:  Transplantation       Date:  2010-12-27       Impact factor: 4.939

Review 2.  Mycophenolate mofetil: fully utilizing its benefits for GvHD prophylaxis.

Authors:  Kentaro Minagawa; Motohiro Yamamori; Yoshio Katayama; Toshimitsu Matsui
Journal:  Int J Hematol       Date:  2012-05-17       Impact factor: 2.490

3.  Serum neutrophil extracellular trap levels predict thrombotic microangiopathy after allogeneic stem cell transplantation.

Authors:  Yasuyuki Arai; Kouhei Yamashita; Kiyomi Mizugishi; Tomohiro Watanabe; Soichiro Sakamoto; Toshiyuki Kitano; Tadakazu Kondo; Hiroshi Kawabata; Norimitsu Kadowaki; Akifumi Takaori-Kondo
Journal:  Biol Blood Marrow Transplant       Date:  2013-09-19       Impact factor: 5.742

4.  Mycophenolate and tacrolimus for graft-versus-host disease prophylaxis for elderly after cord blood transplantation: a matched pair comparison with tacrolimus alone.

Authors:  Naoyuki Uchida; Atsushi Wake; Nobuaki Nakano; Kazuya Ishiwata; Shinsuke Takagi; Masanori Tsuji; Hisashi Yamamoto; Daisuke Kato; Naofumi Matsuno; Kazuhiro Masuoka; Hideki Araoka; Yuki Asano-Mori; Koji Izutsu; Shigeyoshi Makino; Akiko Yoneyama; Shuichi Taniguchi
Journal:  Transplantation       Date:  2011-08-15       Impact factor: 4.939

5.  Risk factors for hypogammaglobulinemia after allo-SCT.

Authors:  Y Arai; K Yamashita; K Mizugishi; T Kondo; T Kitano; M Hishizawa; N Kadowaki; A Takaori-Kondo
Journal:  Bone Marrow Transplant       Date:  2014-03-03       Impact factor: 5.483

6.  Population pharmacokinetics of unbound mycophenolic acid in adult allogeneic haematopoietic cell transplantation: effect of pharmacogenetic factors.

Authors:  Adam Frymoyer; Davide Verotta; Pamala Jacobson; Janel Long-Boyle
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

7.  Pharmacokinetics-based optimal dose-exploration of mycophenolate mofetil in allogeneic hematopoietic stem cell transplantation.

Authors:  Atsuo Okamura; Motohiro Yamamori; Manabu Shimoyama; Yuko Kawano; Hiroki Kawano; Yuriko Kawamori; Shinichiro Nishikawa; Kentaro Minagawa; Kimikazu Yakushijin; Yoshio Katayama; Toshiyuki Sakaeda; Midori Hirai; Toshimitsu Matsui
Journal:  Int J Hematol       Date:  2008-05-14       Impact factor: 2.490

8.  Pre-engraftment syndrome after double-unit cord blood transplantation: a distinct syndrome not associated with acute graft-versus-host disease.

Authors:  Kevin J Patel; Robert D Rice; Rebecca Hawke; Michelle Abboud; Glenn Heller; Andromachi Scaradavou; James W Young; Juliet N Barker
Journal:  Biol Blood Marrow Transplant       Date:  2009-10-24       Impact factor: 5.742

9.  Pharmacokinetics of mycophenolate mofetil in hematopoietic stem cell transplant recipients.

Authors:  Reinier M van Hest; Jeanette K Doorduijn; Brenda C M de Winter; Jan J Cornelissen; Arnold G Vulto; Michael Oellerich; Bob Löwenberg; Ron A A Mathot; Victor William Armstrong; Teun van Gelder
Journal:  Ther Drug Monit       Date:  2007-06       Impact factor: 3.681

10.  Comparison of two mycophenolate mofetil dosing regimens after hematopoietic cell transplantation.

Authors:  P Jacobson; S F El-Massah; J Rogosheske; A Kerr; J Long-Boyle; T DeFor; C Jennissen; C Brunstein; J Wagner; M Tomblyn; D Weisdorf
Journal:  Bone Marrow Transplant       Date:  2009-01-19       Impact factor: 5.483
View more
  3 in total

1.  Drug monitoring for mycophenolic acid in graft-vs-host disease prophylaxis in cord blood transplantation.

Authors:  Hiroyuki Muranushi; Junya Kanda; Yasuyuki Arai; Takero Shindo; Masakatsu Hishizawa; Takashi Yamamoto; Tadakazu Kondo; Kohei Yamashita; Kazuo Matsubara; Akifumi Takaori-Kondo
Journal:  Br J Clin Pharmacol       Date:  2020-05-30       Impact factor: 4.335

Review 2.  Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II.

Authors:  Jeannine S McCune; Meagan J Bemer; Janel Long-Boyle
Journal:  Clin Pharmacokinet       Date:  2016-05       Impact factor: 6.447

Review 3.  Prophylactic and therapeutic treatment of graft-versus-host disease in Japan.

Authors:  Makoto Murata
Journal:  Int J Hematol       Date:  2015-04-12       Impact factor: 2.490
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.